USP18-based negative feedback control is induced by type I and type III interferons and specifically inactivates interferon α response

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  François Newton, Véronique ^a   de Freitas Almeida, Gabriel Magno ^a,d   Payelle Brogard, Béatrice ^a   Monneron, Danièle ^a   Pichard Garcia, Lydiane ^b   Piehler, Jacob ^c   Pellegrini, Sandra ^a   Uzé, Gilles ^a  

^a CNRS   (France)

^b INSERM   (France)

^c UNIVERSITY OF OSNABRÜCK   (Germany)

^d FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2 INTERFERON; BETA INTERFERON; INTERFERON; INTERFERON 3; INTERFERON RECEPTOR; INTERLEUKIN 28; INTERLEUKIN 29; UBIQUITIN; UBIQUITIN SPECIFIC PROTEASE 18; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DESENSITIZATION; FEMALE; GENETIC VARIABILITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; LIVER CELL; NEGATIVE FEEDBACK; PROTEIN BINDING; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

CELL LINE; CELLS, CULTURED; ENDOPEPTIDASES; FEMALE; HUMANS; INTERFERON TYPE I; INTERFERON-ALPHA; INTERFERON-BETA; INTERFERONS; INTERLEUKINS; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROTEIN BINDING; RNA, SMALL INTERFERING;

HEPATITIS C VIRUS;

EID: 79960313095     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022200     Document Type: Article

References (46)

1. Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, et al. (2007) Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 6: 975-990.
2. Sommereyns C, Paul S, Staeheli P, Michiels T, (2008) IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 4: e1000017.
3. Ferrantini M, Capone I, Belardelli F, (2008) Dendritic cells and cytokines in immune rejection of cancer. Cytokine Growth Factor Rev 19: 93-107.
4. Uze G, Schreiber G, Piehler J, Pellegrini S, (2007) The receptor of the type I interferon family. Curr Top Microbiol Immunol 316: 71-95.
5. Moraga I, Harari D, Schreiber G, Uze G, Pellegrini S, (2009) Receptor density is key to the alpha2/beta interferon differential activities. Mol Cell Biol 29: 4778-4787.
6. Jaitin DA, Roisman LC, Jaks E, Gavutis M, Piehler J, et al. (2006) Inquiring into the differential action of interferons (IFNs): an IFN-alpha2 mutant with enhanced affinity to IFNAR1 is functionally similar to IFN-beta. Mol Cell Biol 26: 1888-1897.
7. Kalie E, Jaitin DA, Podoplelova Y, Piehler J, Schreiber G, (2008) The stability of the ternary interferon-receptor complex rather than the affinity to the individual subunits dictates differential biological activities. J Biol Chem 283: 32925-32936.
8. Coelho LF, Magno de Freitas Almeida G, Mennechet FJ, Blangy A, Uze G, (2005) Interferon-alpha and-beta differentially regulate osteoclastogenesis: role of differential induction of chemokine CXCL11 expression. Proc Natl Acad Sci U S A 102: 11917-11922.
9. Coccia EM, Uze G, Pellegrini S, (2006) Negative regulation of type I interferon signaling: facts and mechanisms. Cell Mol Biol (Noisy-le-grand) 52: 77-87.
10. Sarasin-Filipowicz M, Wang X, Yan M, Duong FH, Poli V, et al. (2009) Alpha interferon induces long-lasting refractoriness of JAK-STAT signaling in the mouse liver through induction of USP18/UBP43. Mol Cell Biol 29: 4841-4851.
11. Randall G, Chen L, Panis M, Fischer AK, Lindenbach BD, et al. (2006) Silencing of USP18 potentiates the antiviral activity of interferon against hepatitis C virus infection. Gastroenterology 131: 1584-1591.
12. Malakhov MP, Malakhova OA, Kim KI, Ritchie KJ, Zhang DE, (2002) UBP43 (USP18) specifically removes ISG15 from conjugated proteins. J Biol Chem 277: 9976-9981.
13. Malakhova OA, Kim KI, Luo JK, Zou W, Kumar KG, et al. (2006) UBP43 is a novel regulator of interferon signaling independent of its ISG15 isopeptidase activity. EMBO J 25: 2358-2367.
14. Chen L, Borozan I, Feld J, Sun J, Tannis LL, et al. (2005) Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 128: 1437-1444.
15. Sarasin-Filipowicz M, Oakeley EJ, Duong FH, Christen V, Terracciano L, et al. (2008) Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A 105: 7034-7039.
16. Uze G, Monneron D, (2007) IL-28 and IL-29: newcomers to the interferon family. Biochimie 89: 729-734.
17. Kim KI, Yan M, Malakhova O, Luo JK, Shen MF, et al. (2006) Ube1L and protein ISGylation are not essential for alpha/beta interferon signaling. Mol Cell Biol 26: 472-479.
18. Knobeloch KP, Utermohlen O, Kisser A, Prinz M, Horak I, (2005) Reexamination of the role of ubiquitin-like modifier ISG15 in the phenotype of UBP43-deficient mice. Mol Cell Biol 25: 11030-11034.
19. Osiak A, Utermohlen O, Niendorf S, Horak I, Knobeloch KP, (2005) ISG15, an interferon-stimulated ubiquitin-like protein, is not essential for STAT1 signaling and responses against vesicular stomatitis and lymphocytic choriomeningitis virus. Mol Cell Biol 25: 6338-6345.
20. Durfee LA, Kelley ML, Huibregtse JM, (2008) The basis for selective E1-E2 interactions in the ISG15 conjugation system. J Biol Chem 283: 23895-23902.
21. Liu LQ, Ilaria R Jr, Kingsley PD, Iwama A, van Etten RA, et al. (1999) A novel ubiquitin-specific protease, UBP43, cloned from leukemia fusion protein AML1-ETO-expressing mice, functions in hematopoietic cell differentiation. Mol Cell Biol 19: 3029-3038.
22. Schwer H, Liu LQ, Zhou L, Little MT, Pan Z, et al. (2000) Cloning and characterization of a novel human ubiquitin-specific protease, a homologue of murine UBP43 (Usp18). Genomics 65: 44-52.
23. Dondi E, Pattyn E, Lutfalla G, Van Ostade X, Uze G, et al. (2001) Down-modulation of type 1 interferon responses by receptor cross-competition for a shared Jak kinase. J Biol Chem 276: 47004-47012.
24. Severa M, Remoli ME, Giacomini E, Ragimbeau J, Lande R, et al. (2006) Differential responsiveness to IFN-{alpha} and IFN-{beta} of human mature DC through modulation of IFNAR expression. J Leukoc Biol 79: 1286-1294.
25. Duex JE, Sorkin A, (2009) RNA interference screen identifies Usp18 as a regulator of epidermal growth factor receptor synthesis. Mol Biol Cell 20: 1833-1844.
26. Coccia EM, Severa M, Giacomini E, Monneron D, Remoli ME, et al. (2004) Viral infection and Toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur J Immunol 34: 796-805.
27. Ank N, West H, Bartholdy C, Eriksson K, Thomsen AR, et al. (2006) Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol 80: 4501-4509.
28. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, et al. (2003) IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 4: 69-77.
29. Marcello T, Grakoui A, Barba-Spaeth G, Machlin ES, Kotenko SV, et al. (2006) Interferons alpha and lambda Inhibit Hepatitis C Virus Replication With Distinct Signal Transduction and Gene Regulation Kinetics. Gastroenterology 131: 1887-1898.
30. Zhou Z, Hamming OJ, Ank N, Paludan SR, Nielsen AL, et al. (2007) Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases. J Virol 81: 7749-7758.
31. Asselah T, Bieche I, Narguet S, Sabbagh A, Laurendeau I, et al. (2008) Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Gut 57: 516-524.
32. Chen L, Borozan I, Sun J, Guindi M, Fischer S, et al. (2010) Cell-type specific gene expression signature in liver underlies response to interferon therapy in chronic hepatitis C infection. Gastroenterology 138: 1123-1133 e1121-1123.
33. Honda M, Sakai A, Yamashita T, Nakamoto Y, Mizukoshi E, et al. (2010) Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 139: 499-509.
34. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, et al. (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461: 399-401.
35. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, et al. (2009) IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 41: 1100-1104.
36. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, et al. (2009) Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41: 1105-1109.
37. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, et al. (2009) Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461: 798-801.
38. Abe H, Hayes CN, Ochi H, Maekawa T, Tsuge M, et al. (2010) IL28 Variation Affects Expression of Interferon Stimulated Genes and Effect of Peg-Interferon and Ribavirin Therapy. J Hepatol.
39. Dill MT, Duong FH, Vogt JE, Bibert S, Bochud PY, et al. (2010) Interferon-Induced Gene Expression Is a Stronger Predictor of Treatment Response Than IL28B Genotype in Patients With Hepatitis C. Gastroenterology.
40. Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, et al. (2010) IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 52: 1888-1896.
41. Ferrini JB, Ourlin JC, Pichard L, Fabre G, Maurel P, (1998) Human hepatocyte culture. Methods Mol Biol 107: 341-352.
42. Slutzki M, Jaitin DA, Yehezkel TB, Schreiber G, (2006) Variations in the unstructured C-terminal tail of interferons contribute to differential receptor binding and biological activity. J Mol Biol 360: 1019-1030.
43. Jaks E, Gavutis M, Uze G, Martal J, Piehler J, (2007) Differential receptor subunit affinities of type I interferons govern differential signal activation. J Mol Biol 366: 525-539.
44. Marijanovic Z, Ragimbeau J, van der Heyden J, Uze G, Pellegrini S, (2007) Comparable potency of IFNalpha2 and IFNbeta on immediate JAK/STAT activation but differential down-regulation of IFNAR2. Biochem J 407: 141-151.
45. Mogensen KE, Uze G, (1986) Radioiodination of human alpha interferons by the chloramine T method. Methods Enzymol 119: 267-276.
46. Potu H, Sgorbissa A, Brancolini C, (2010) Identification of USP18 as an important regulator of the susceptibility to IFN-alpha and drug-induced apoptosis. Cancer Res 70: 655-665.